Clinical Report: A Bibliometric Study on Immune Checkpoint Inhibitor-Associated Pneumonitis

Overview

This bibliometric study analyzes the evolution of research on immune checkpoint inhibitor-associated pneumonitis (CIP) and its diagnostic approaches. It highlights the increasing publication trends and the challenges in diagnosing CIP due to overlapping symptoms with other conditions.

Background

CIP is a significant pulmonary toxicity associated with cancer immunotherapy, complicating the management of patients receiving immune checkpoint inhibitors. Accurate diagnosis is critical, as symptoms can mimic other conditions, leading to potential delays in treatment. Understanding the research landscape is essential for improving diagnostic strategies and patient outcomes.

Data Highlights

Key Findings

• Research on CIP has significantly increased since 2015, with a notable acceleration post-2019.
• China leads in the number of publications, while the United States has the highest citation impact.
• Key themes in recent research include diagnosis, differential diagnosis, and imaging features.
• Diagnostic assessment of CIP is complicated by overlapping symptoms with other pulmonary conditions.

Clinical Implications

Clinicians should be aware of the diagnostic challenges associated with CIP, as symptoms can overlap with other pulmonary complications. Enhanced understanding of current research trends may aid in the development of more effective diagnostic and management strategies.

Conclusion

The evolution of research on CIP underscores the need for improved diagnostic approaches to differentiate it from other pulmonary complications in patients undergoing immunotherapy.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)
2. Frontiers in Immunology, 2026 -- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025)
3. Frontiers in Immunology, 2026 -- Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review
4. NCCN Guidelines® Insights, 2024 -- Management of Immunotherapy-Related Toxicities, Version 2.2024
5. New England Journal of Medicine, 2017 -- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
6. Frontiers in Oncology — Immune Checkpoint Inhibitors: efficacy, safety, and biomarkers - a systematic review
7. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 - PubMed
8. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | New England Journal of Medicine
9. Comparative Risks of Pneumonitis Amongst Immune Checkpoint Inhibitors in Patients with Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials - PMC